Latest News on IRON

Financial News Based On Company


Advertisement
Advertisement

Disc Medicine (IRON), Why Is Its Latest Update Drawing Attention?

https://sg.finance.yahoo.com/news/disc-medicine-iron-why-latest-051631386.html
Disc Medicine (IRON) has garnered attention after reporting third-quarter and nine-month results, showing a quarterly net loss of US$59.54 million and a year-to-date loss of US$182.57 million. Despite short-term share price declines, a longer-term positive momentum exists, though recent losses and no current revenue raise questions about potential upside outweighing funding risks. The company plans to resubmit its bitopertin NDA by the end of 2026, which could introduce an initial revenue stream.

Morgan Stanley maintains Disc Medicine at Overweight, raises price target to $104 from $92

https://www.tradingview.com/news/tradingview:67d598084e7f0:0-morgan-stanley-maintains-disc-medicine-at-overweight-raises-price-target-to-104-from-92/
Morgan Stanley has maintained its "Overweight" rating for Disc Medicine and increased its price target from $92 to $104, indicating a potential upside of 35.8% from the stock's closing price on November 17. This adjustment reflects continued confidence in the company, with other analysts also holding "Buy" or "Overweight" ratings and price targets ranging from $92 to $132 in recent weeks.

IRON: Bitopertin posts >70% fewer pain attacks as next-stage filings and trials approach

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4682213:0-iron-bitopertin-posts-70-fewer-pain-attacks-as-next-stage-filings-and-trials-approach/
Disc Medicine, Inc. (IRON) has reported a greater than 70% reduction in phototoxic pain attacks with Bitopertin in Phase III trials, leading to a planned NDA resubmission by year-end. The company's priorities for the next year include a European MAA submission and advancing its myelofibrosis and PV programs towards Phase III. This information is based on an audio transcript from the Jefferies Global Healthcare Conference on November 18, 2026.

IRON: Phase III EPP success leads a pipeline advancing toward pivotal studies and 2027 milestones

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4659265:0-iron-phase-iii-epp-success-leads-a-pipeline-advancing-toward-pivotal-studies-and-2027-milestones/
Disc Medicine, Inc. (IRON) has announced successful Phase III EPP endpoints for Bitopertin, with resubmission anticipated by late 2026 and FDA action targeted for mid-2027. The company is also advancing Phase II programs for myelofibrosis anemia, IBD anemia, and polycythemia vera, with further data and development plans to be shared at ASH and in 2027. This information was based on the UBS Global Biopharma Conference 2026 audio transcript from November 17, 2026.

Form 4 Disc Medicine Inc: William Jacob Savage (Chief Medical Officer) For: 10 November

https://ca.investing.com/news/stock-market-news/form-4-disc-medicine-inc-william-jacob-savage-chief-medical-officer-for-10-november-93CH-4955430
This article reports on a Form 4 filing for Disc Medicine Inc, specifically concerning William Jacob Savage, the Chief Medical Officer, for transactions dated November 10. Form 4 filings disclose changes in beneficial ownership of a company's securities by insiders. This indicates a public record of a transaction by a key executive at Disc Medicine Inc.
Advertisement

Form 144 DISC MEDICINE INC For: 10 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-disc-medicine-inc-for-10-november-93CH-4948042
This article reports on the filing of Form 144 for DISC MEDICINE INC on November 10. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity or significant share transactions. The brief announcement provides no further details on the specifics of the filing.

Guggenheim initiates coverage of Disc Medicine at Buy, sets price target at $132

https://www.tradingview.com/news/tradingview:c8f328c1293aa:0-guggenheim-initiates-coverage-of-disc-medicine-at-buy-sets-price-target-at-132/
Guggenheim has initiated coverage of Disc Medicine (IRON) with a Buy rating and a price target of $132, implying a 67.3% upside from its November 6 close. This new rating follows several other recent analyst actions, with price targets ranging from $92 to $127 over the past 30 days. Investors can explore more price target data and analyst recommendations on TradingView's platform.

Guggenheim initiates Disc Medicine stock coverage with buy rating

https://www.investing.com/news/analyst-ratings/guggenheim-initiates-disc-medicine-stock-coverage-with-buy-rating-93CH-5010589
Guggenheim has initiated coverage on Disc Medicine Inc. (NASDAQ:IRON) with a buy rating and a price target of $132.00, citing the company's portfolio of treatments for blood disorders, which includes bitopertin, selcodebart, and DISC-3405. The firm projects over $3 billion in risk-adjusted peak sales for these treatments across various conditions. This positive outlook follows Disc Medicine's recent 39% stock surge after favorable Phase 3 APOLLO trial results, and aligns with other analysts who have also raised their price targets for the company.

Wall Street Zen Upgrades Disc Medicine (NASDAQ:IRON) to "Hold"

https://www.marketbeat.com/instant-alerts/analyst-wall-street-zen-upgrades-disc-medicine-nasdaq-iron-to-hold-2026-11-07/
Wall Street Zen has upgraded Disc Medicine (NASDAQ:IRON) from a "sell" to a "hold" rating, aligning with a broader "Moderate Buy" consensus from other analysts. Several firms, including Cantor Fitzgerald and Wells Fargo, also raised their price targets for the stock. This upgrade follows Disc Medicine reporting a narrower-than-expected quarterly loss of $1.53 per share, beating analyst estimates.

Disc Medicine enters sales agreement with TD Cowen for $189.93M stock offering

https://scanx.trade/stock-market-news/ipo/disc-medicine-enters-sales-agreement-td-cowen-189-93m-stock-offering/55467426
Disc Medicine Inc. has signed a sales agreement with TD Cowen to offer and sell up to $189.93 million worth of its common stock. This at-the-market offering was disclosed in a recent SEC filing. The deal establishes TD Cowen as the agent for the stock sales.
Advertisement

Form 424B5 Disc Medicine Inc For: 5 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-424b5-disc-medicine-inc-for-5-november-93CH-4936631
The article announces the filing of Form 424B5 by Disc Medicine Inc. on November 5. This is a standard regulatory filing, likely related to a prospectus or offering circular, providing details about the company's securities. The brief notice highlights the immediate availability of this financial document.

Form 424B5 Disc Medicine Inc For: 5 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-424b5-disc-medicine-inc-for-5-november-93CH-4962872
This article announces the filing of Form 424B5 by Disc Medicine Inc. on November 5. The content is brief, primarily serving as a notification of the regulatory filing and providing a link to view the document.

Form 424B5 Disc Medicine, Inc.

https://www.streetinsider.com/SEC+Filings/Form+424B5+Disc+Medicine%2C+Inc./27301710.html
Disc Medicine, Inc. has filed a Form 424B5 prospectus supplement to offer and sell up to $189,925,765 of common stock through TD Securities (USA) LLC. The company is a clinical-stage biopharmaceutical firm focused on treatments for hematologic diseases, with lead product candidates bitopertin for erythropoietic porphyrias and selcodebart for anemia of myelofibrosis. The proceeds from this offering will primarily fund research, clinical development, and potential commercialization of its product candidates.

Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update

https://www.manilatimes.net/2026/11/05/tmt-newswire/globenewswire/disc-medicine-reports-third-quarter-2026-financial-results-and-provides-business-update/2463030
Disc Medicine announced strong third-quarter 2026 financial results, including approximately $683 million in cash and a public offering that extended its cash runway into 2030. The company reported positive Phase 3 APOLLO trial results for bitopertin in erythropoietic protoporphyria (EPP), with an NDA resubmission planned by the end of 2026. Additionally, Disc Medicine provided updates on its selcodebart and DISC-3405 programs, with further data presentations expected at the 68th American Society of Hematology annual meeting in December 2026.

Disc Medicine Phase 3 trial cuts PPIX 41.4% vs placebo | IRON Stock News

https://www.stocktitan.net/news/IRON/disc-medicine-reports-third-quarter-2026-financial-results-and-5rqul5ok19l1.html
Disc Medicine announced positive results from its pivotal Phase 3 APOLLO trial of bitopertin for erythropoietic protoporphyria (EPP), meeting all primary and secondary endpoints. Bitopertin significantly reduced the blood biomarker metal-free PPIX by 41.4% and increased monthly pain-free time in light by 12.2 hours. The company plans to resubmit its U.S. approval application by the end of 2026, anticipating an FDA decision by mid-2027, and reported a strong financial position with an expected cash runway into 2030.
Advertisement

Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting

https://www.quantisnow.com/insight/disc-medicine-announces-multiple-presentations-across-portfolio-at-the-68th-6771707
Disc Medicine will present data from several programs, including Phase 2 trials for myelofibrosis (MF) anemia and polycythemia vera (PV), a Phase 1b sickle cell disease study, and baseline data from the Phase 3 APOLLO trial, at the American Society of Hematology (ASH) meeting from December 12-15, 2026. While some abstracts contain previously presented data, new results will be revealed at the conference, followed by a management call on December 16 to discuss findings and next steps.

Disc Medicine to Participate in Upcoming Investor Conferences

https://www.manilatimes.net/2026/11/02/tmt-newswire/globenewswire/disc-medicine-to-participate-in-upcoming-investor-conferences/2459582
Disc Medicine, Inc. (NASDAQ:IRON) announced that its management will participate in fireside chats and investor meetings at several upcoming investor conferences in November 2026. These conferences include the Guggenheim 3rd Annual Healthcare Innovation Conference, Stifel 2026 Healthcare Conference, UBS Global Biopharma Conference, Jefferies London Global Healthcare Conference, and the Truist BioPharma Symposium. Live webcasts of the fireside chats will be available on the company's investor relations website, with archived replays provided after each event.

Four Disc Medicine conference chats will be webcast live in November

https://www.stocktitan.net/news/IRON/disc-medicine-to-participate-in-upcoming-investor-5xngmtxru2g0.html
Disc Medicine (NASDAQ: IRON) announced that its management will participate in fireside chats at four investor conferences between November 9 and November 18, 2026. These events include conferences hosted by Guggenheim, Stifel, UBS, and Jefferies, where management will also hold investor meetings. Live webcasts and replays of these fireside chats will be accessible via the company's investor relations website.

Disc Medicine, Inc. (IRON) Seasonal returns chart

https://au.finance.yahoo.com/quote/IRON/seasonality/
This article presents a seasonal returns chart for Disc Medicine, Inc. (IRON), showing the average monthly price return from 2020 to 2026. The stock closed at $80.84 on October 30, with a slight decrease of 2.41% during the trading day. The chart aims to illustrate historical seasonality patterns for the company's stock performance.

Disc Medicine (IRON) Expected to Release Earnings on Thursday

https://www.marketbeat.com/instant-alerts/upcoming-disc-medicine-iron-expected-to-release-earnings-on-thursday-2026-10-29/
Disc Medicine (NASDAQ:IRON) is anticipated to release its Q3 2026 earnings before market open on Thursday, November 5th, with analysts forecasting a loss of $1.63 per share and $1.88 million in revenue. The company previously exceeded estimates in Q2 with a loss of $1.54 per share. IRON shares have seen a 4.1% increase to $83.20, while analysts generally maintain a "Moderate Buy" rating with an average price target of $122.70, despite recent insider share sales totaling approximately $13.6 million.
Advertisement

Learn Why The Bull Case For Disc Medicine (IRON) Could Change Following Phase 3 Trial Success

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine/news/learn-why-the-bull-case-for-disc-medicine-iron-could-change
Disc Medicine announced positive Phase 3 trial results for bitopertin in EPP and XLP, meeting all primary and secondary endpoints. This success, coupled with a US$450 million equity offering, positions the company to resubmit its NDA by the end of 2026 and aims for FDA approval by mid-2027, potentially shifting its investment narrative from a pre-revenue stage to a commercial product launch. Analysts project significant revenue and earnings growth for Disc Medicine by 2029 based on bitopertin's potential.

Form 13D/A DISC MEDICINE For: 26 October By Investing.com

https://uk.investing.com/news/stock-market-news/form-13da-disc-medicine-for-26-october-93CH-4932665
This article from Investing.com announces the filing of a Form 13D/A for DISC MEDICINE, pertaining to October 26. The content provides the title and a re-iteration of the filing without further details within the article body. It also includes market data for various indices, commodities, and shares, along with popular articles and market movers.

Weekly Recap: Disc Medicine, Inc. $450M offering and 41.4% PPIX drop

https://www.tradingview.com/news/tradingview:cf9454be6d8d8:0-weekly-recap-disc-medicine-inc-450m-offering-and-41-4-ppix-drop/
Disc Medicine, Inc. (NASDAQ:IRON) saw a significant surge after its Phase 3 APOLLO trial demonstrated that bitopertin reduced metal-free PPIX by 41.4% and increased pain-free light hours by 12.2. This positive outcome prompted plans for an FDA resubmission by the end of 2026, an upsized $450M public offering, and higher price targets from analysts.

Disc Medicine (IRON) Jumped, What Is Behind The Move?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine/news/disc-medicine-iron-jumped-what-is-behind-the-move/amp
Disc Medicine (IRON) saw its stock jump after announcing positive Phase 3 APOLLO data for bitopertin and a subsequent US$450 million stock offering. Despite a mixed year-to-date performance, the company shows strong long-term momentum, trading at a discount to analyst targets. The market views Disc Medicine as potentially undervalued, with a fair value of $116.67, driven by its multiple potential blockbuster assets and cash runway extending to 2029.

Form 13D/A DISC MEDICINE For: 26 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-13da-disc-medicine-for-26-october-93CH-2758485
This article announces the filing of Form 13D/A for DISC MEDICINE on October 26, 2026. The content is brief and primarily serves as a notification of the SEC filing, with no further details provided within the article itself. It also mentions IRON with a slight price increase.
Advertisement

Disc Medicine, Inc. Estimates – NASDAQ:IRON

https://www.tradingview.com/symbols/NASDAQ-IRON/financials-estimates/
This article provides an overview of Disc Medicine, Inc. (NASDAQ:IRON) financials and estimates on TradingView. It allows users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform enables comparison of actual results with average, high, and low estimates, and visualization of trends over time for both annual and quarterly data.

Form 4 Disc Medicine Inc: Kevin Bitterman (Director) For: 19 October By Investing.com

https://za.investing.com/news/stock-market-news/form-4-disc-medicine-inc-kevin-bitterman-director-for-19-october-93CH-4517920
This article reports on a Form 4 filing for Disc Medicine Inc, indicating that Director Kevin Bitterman made a transaction on October 19. The article provides the title of the filing and the date of the reported activity. No further details about the transaction are disclosed within the provided content.

Form 4 Disc Medicine Inc: Kevin Bitterman (Director) For: 19 October

https://ng.investing.com/news/stock-market-news/form-4-disc-medicine-inc-kevin-bitterman-director-for-19-october-93CH-2749797
The article reports on a Form 4 filing for Disc Medicine Inc, detailing an insider transaction by Kevin Bitterman, a Director, on October 19. Form 4 filings are regulatory documents that disclose changes in the ownership of company stock by insiders, including directors and officers. This specific filing indicates a transaction by Kevin Bitterman related to Disc Medicine Inc.

Disc Medicine Raises $450 Million in Public Offering to Extend Cash Runway Into 2030

https://www.tradingview.com/news/tradingview:f2b731d3b600f:0-disc-medicine-raises-450-million-in-public-offering-to-extend-cash-runway-into-2030/
Disc Medicine (IRON) has successfully raised approximately $422.4 million in net proceeds through a public offering of 6 million common shares at $75 per share. The underwriters have a 30-day option for an additional 900,000 shares. This offering, which closed on October 22, 2026, is expected to fund the company's operations, capital expenditures, and debt service until 2030.

Form 8K Disc Medicine Inc For: 22 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-disc-medicine-inc-for-22-october-93CH-4898088
This article from Investing.com announces that Disc Medicine Inc. has filed a Form 8K for October 22. The 8K filing is a crucial document for investors, as it notifies the public of unscheduled material events or corporate changes that could be important to shareholders.
Advertisement

WilmerHale Advises Underwriters in Disc Medicine’s Upsized $450 Million Public Offering

https://www.wilmerhale.com/en/insights/news/20261022-wilmerhale-advises-underwriters-in-disc-medicines-upsized-450-million-public-offering
WilmerHale advised the underwriters in Disc Medicine, Inc.'s upsized public offering of 6,000,000 shares of common stock, which generated approximately $450 million in gross proceeds. Disc Medicine is a clinical-stage biopharmaceutical company focused on treatments for serious hematologic diseases. The offering also included a 30-day option for underwriters to purchase an additional 900,000 shares.

Form 4 Disc Medicine Inc: Kevin Bitterman (Director) For: 19 October

https://au.investing.com/news/stock-market-news/form-4-disc-medicine-inc-kevin-bitterman-director-for-19-october-93CH-4705954
This article reports a Form 4 filing for Disc Medicine Inc, indicating an insider transaction involving director Kevin Bitterman. The transaction date is specified as October 19. The article provides minimal details beyond the filing notification itself.

Disc Medicine, Inc. (IRON) options chain

https://uk.finance.yahoo.com/quote/IRON/options/?date=1799971200&straddle=false&type=all
This article provides the options chain for Disc Medicine, Inc. (IRON), displaying its current stock price and options data. As of the closing bell on January 15, 2027, the stock stood at $75.03, down 1.28%. The options chain currently shows no available calls or puts.

Disc Medicine (NASDAQ:IRON) Director Sells 10,994 Shares of Stock

https://www.marketbeat.com/instant-alerts/insider-disc-medicine-nasdaq-iron-director-sells-10994-shares-of-stock-2026-10-21/
Disc Medicine director Kevin Bitterman sold 10,994 shares of IRON stock for approximately $879,190 on October 19th, under a pre-arranged trading plan, reducing his direct holdings by 45.23%. Following this and other recent sales, the company's shares fell 4.4% to $76.00 in heavy trading, though analysts maintain a "Moderate Buy" consensus with a $122.70 price target. The company, with a $2.92 billion market cap, recently beat EPS estimates and shows significant institutional ownership.

A shareholder proposes selling 33,461 Disc Medicine (Nasdaq: IRON) shares valued at $2.66M.

https://www.stocktitan.net/sec-filings/IRON/144-disc-medicine-inc-sec-filing-c5068bcd7459.html
Atlas Venture Fund X, a shareholder in Disc Medicine, Inc. (IRON), has filed a notice for a proposed sale of 33,461 shares of common stock, valued at approximately $2.66 million. The shares were acquired through a private placement in May 2020, with the proposed sale date listed as October 21, 2026, on Nasdaq. This Form 144 filing indicates a large block of shares entering the market.
Advertisement

A shareholder proposes selling 2,388 Disc Medicine (Nasdaq: IRON) shares.

https://www.stocktitan.net/sec-filings/IRON/144-disc-medicine-inc-sec-filing-0b481152b657.html
Atlas Venture Opportunity Fund II, a shareholder in Disc Medicine, Inc. (IRON), has filed a Form 144 notice to propose the sale of 2,388 common shares with an aggregate market value of $188,484.84. The proposed sale date is listed as October 20, 2026, with Merrill Lynch as the broker. These shares were initially acquired by Atlas Venture Opportunity Fund II in a private placement from the issuer on May 1, 2020.

How Phase 3 Success At Disc Medicine (IRON) Has Changed Its Investment Story

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine/news/how-phase-3-success-at-disc-medicine-iron-has-changed-its-in
Disc Medicine's APOLLO Phase 3 trial for bitopertin successfully met its primary and secondary endpoints for erythropoietic protoporphyria and X-linked protoporphyria. This positive clinical data is paired with a planned US$350 million equity offering, indicating a strategic move towards commercialization. The company's investment narrative is now shifting, focusing on regulatory milestones and funding for pre-launch activities, though it faces risks related to profitability and sales force expansion.

Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.

https://www.streetinsider.com/SEC+Filings/Form+144+Disc+Medicine%2C+Inc.+Filed+by%3A+Atlas+Venture+Opportunity+Fund+I%2C+L.P./27211293.html
Atlas Venture Opportunity Fund I, L.P. has filed a Form 144 with the SEC, indicating its intent to sell 2,869 shares of Disc Medicine, Inc. (NASDAQ: IRON) common stock. The aggregate market value of these securities is $226,450.17, and the shares were originally acquired through a private placement on May 1, 2020. The sale is planned for October 20, 2026, via Merrill Lynch.

Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock

https://www.daily-tribune.com/online_features/press_releases/disc-medicine-announces-pricing-of-450-million-upsized-public-offering-of-common-stock/article_8a6a6f93-2661-56e1-833b-8eadb98611bd.html
Disc Medicine, Inc. (NASDAQ: IRON) has priced an upsized underwritten public offering of 6,000,000 shares of its common stock at $75.00 per share, expecting to raise $450 million. The company plans to use the net proceeds, along with existing funds, to advance research and clinical development of product candidates, support potential commercialization of bitopertin for EPP and XLP, and for general corporate purposes. The offering is anticipated to close on October 22, 2026.

Disc Medicine follows up positive bitopertin Phase III with USD 350m offering

https://allsci.com/news/biotech/disc-medicine-offering-proposes-usd-350m-after/
Disc Medicine, Inc. (Nasdaq: IRON) has initiated a proposed public offering of $350 million in common stock and pre-funded warrants, following positive topline results from its pivotal Phase III APOLLO trial for bitopertin in erythropoietic protoporphyria (EPP). The proceeds are intended to fund the potential commercialization of bitopertin for EPP and X-linked protoporphyria (XLP), advance other candidates, and support broader R&D efforts. The company also reported that the Phase III APOLLO trial successfully met its co-primary and all secondary endpoints.
Advertisement

Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday

https://www.benzinga.com/trading-ideas/movers/26/10/62439669/silence-therapeutics-disc-medicine-veradermics-and-other-big-stocks-moving-higher-on-monday
U.S. stocks saw mixed performance on Monday, with several companies experiencing significant gains. Silence Therapeutics PLC surged after agreeing to be acquired by Merck KGaA, while Disc Medicine Inc rose following positive Phase 3 trial results. Veradermics Inc also saw an increase due to successful Phase 3 clinical trial data for its hair growth treatment.

Disc Medicine (IRON) Launches $350M Stock Offering to Fund Clinical Development

https://www.gurufocus.com/news/9130613/disc-medicine-iron-launches-350m-stock-offering-to-fund-clinical-development
Disc Medicine Inc (NASDAQ: IRON) has announced a $350 million public offering of common stock and pre-funded warrants to fund clinical development and commercialization, particularly for its lead candidate bitopertin. As a clinical-stage biotech with no revenue, traditional valuation metrics are not applicable, and its GF Score™ of 35/100 indicates strong financial stability but weak profitability. Insider selling and guru position trimming suggest caution among informed investors regarding the stock's speculative nature and reliance on future clinical milestones.

Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund II, L.P.

https://www.streetinsider.com/SEC+Filings/Form+144+Disc+Medicine%2C+Inc.+Filed+by%3A+Atlas+Venture+Opportunity+Fund+II%2C+L.P./27204494.html
Atlas Venture Opportunity Fund II, L.P. has filed a Form 144 to sell 4,942 shares of Disc Medicine, Inc. common stock. The aggregate market value of the shares to be sold is $280,903.28, and the sale is scheduled for October 19, 2026, on Nasdaq. These shares were acquired on May 1, 2020, through a private placement from the issuer.

A shareholder proposes selling 14,414 Disc Medicine (IRON) shares through Merrill Lynch.

https://www.stocktitan.net/sec-filings/IRON/144-disc-medicine-inc-sec-filing-4dd3113f886a.html
Atlas Venture Fund X, a shareholder of Disc Medicine (IRON), has proposed selling 14,414 common shares through Merrill Lynch. The aggregate market value of these shares is $819,291.76, with an approximate sale date of October 19, 2026. These shares were originally acquired in a private placement on May 1, 2020.

Disc Medicine launches $350 million stock offering

https://www.investing.com/news/company-news/disc-medicine-launches-350-million-stock-offering-93CH-4958211
Disc Medicine Inc. (NASDAQ:IRON) has initiated an underwritten public offering of $350 million in common stock and pre-funded warrants, with underwriters having an option to purchase an additional $52.5 million in shares. The biopharmaceutical company plans to use the proceeds for research, clinical development, potential commercialization of bitopertin, and general corporate purposes. The offering is subject to market conditions and is being managed by Jefferies, Leerink Partners, Morgan Stanley, and Cantor.
Advertisement

Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study

https://www.benzinga.com/markets/biotech/26/10/62445534/disc-medicine-delivers-promise-for-patients-with-sunlight-sensitivity-in-successful-pivotal-study
Disc Medicine announced positive results from its APOLLO Phase 3 trial for bitopertin, a treatment for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), conditions causing severe sunlight sensitivity. The trial successfully met all primary and secondary endpoints, demonstrating a significant reduction in a key biomarker and increased pain-free light exposure time. Bitopertin was also well-tolerated, and Disc Medicine plans to resubmit a new drug application to the FDA by year-end, with a decision expected by mid-2027.

Disc Medicine rallies 32% as investors await Bitopertin trial results (IRON:NASDAQ)

https://seekingalpha.com/news/4654110-disc-medicine-rallies-32-as-investors-await-phase-3-results
Disc Medicine shares surged by 32% in premarket trading as investors anticipate the topline results from its Phase 3 APOLLO trial. The trial is evaluating Bitopertin, an experimental treatment for erythropoietic protoporphyria (EPP), a rare disorder characterized by severe sun sensitivity. The upcoming results are a key driver for the stock's significant movement.

Disc Medicine to Host Webcast on APOLLO Phase 3 Topline Results for Bitopertin in EPP

https://www.quiverquant.com/news/Disc+Medicine+to+Host+Webcast+on+APOLLO+Phase+3+Topline+Results+for+Bitopertin+in+EPP
Disc Medicine, Inc. announced it will host a webcast on October 19, 2026, at 8:00 a.m. ET to discuss the topline results from its APOLLO Phase 3 trial of bitopertin for erythropoietic protoporphyria (EPP). Bitopertin, an investigational oral inhibitor, aims to be the first disease-modifying therapy for EPP. The company obtained global rights to bitopertin from Roche in May 2021.

Disc spins past FDA rejection with ‘overwhelmingly positive’ phase 3 data for rare disease drug

https://www.fiercebiotech.com/biotech/disc-spins-past-fda-rejection-overwhelmingly-positive-phase-3-data
Disc Medicine's drug candidate bitopertin achieved its co-primary and secondary endpoints in a phase 3 trial for erythropoietic protoporphyria (EPP), leading to a 55% jump in Disc shares. This positive data follows an earlier FDA rejection and provides a clearer link between the drug's impact on a biomarker and increased sunlight tolerance for patients. The company plans to refile for FDA approval by year-end, anticipating a decision by mid-2027, with BMO Capital Markets analysts projecting peak sales of $1.2 billion.

Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints

https://finance.yahoo.com/healthcare/articles/disc-medicine-surges-38-bitopertin-145200503.html
Disc Medicine's experimental drug bitopertin successfully met all endpoints in its pivotal Phase 3 APOLLO trial for erythropoietic protoporphyria (EPP), causing the company's stock to surge 38%. The drug significantly reduced PPIX levels and increased light exposure time without pain, along with improving patients' quality of life. Disc Medicine plans to resubmit a New Drug Application to the FDA by the end of 2026, with a decision expected by mid-2027.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement